SION-2222 (formerly ABBV-2222/GLPG2222) is a type of CFTR modulator called a corrector. Correctors are drugs designed to fix and restore the function of the defective CFTR protein. The corrected CFTR then moves to the cell surface, where it functions as a chloride channel and helps maintain the right balance of fluid in the airways.

Status

A Phase 1 study of SION-2222 is currently underway in healthy volunteers. The study is evaluating SION-2222 in combination with SION-451, another CFTR corrector.

A Phase 2 study to test the safety and tolerability of SION-2222 was previously completed. The study was for people with CF who have two copies of the F508del CFTR mutation.

Sponsor

This program is sponsored by Sionna and partially funded by the Cystic Fibrosis Foundation.